CN108619143A - A kind of composition and its purposes for preventing infectious laryngotracheitis of chicken - Google Patents
A kind of composition and its purposes for preventing infectious laryngotracheitis of chicken Download PDFInfo
- Publication number
- CN108619143A CN108619143A CN201810720166.9A CN201810720166A CN108619143A CN 108619143 A CN108619143 A CN 108619143A CN 201810720166 A CN201810720166 A CN 201810720166A CN 108619143 A CN108619143 A CN 108619143A
- Authority
- CN
- China
- Prior art keywords
- composition
- blackberry lily
- chicken
- infectious laryngotracheitis
- general flavone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/30—Animal feeding-stuffs from material of plant origin, e.g. roots, seeds or hay; from material of fungal origin, e.g. mushrooms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/116—Heterocyclic compounds
- A23K20/132—Heterocyclic compounds containing only one nitrogen as hetero atom
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/116—Heterocyclic compounds
- A23K20/137—Heterocyclic compounds containing two hetero atoms, of which at least one is nitrogen
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/70—Feeding-stuffs specially adapted for particular animals for birds
- A23K50/75—Feeding-stuffs specially adapted for particular animals for birds for poultry
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Epidemiology (AREA)
- Animal Husbandry (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Botany (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Birds (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medical Informatics (AREA)
- Emergency Medicine (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention provides the purposes of a kind of composition and its prevention infectious laryngotracheitis of chicken, are related to field of veterinary.The composition includes his Wei of lacidipine and Dacca.This composition passes through the compounding between his Wei of lacidipine and Dacca both active components, there is potent killing effect to avian infectious laryngotracheitis virus, it can inhibit the propagation of avian infectious laryngotracheitis virus, it effectively reduces and suffers from the fowl death rate, and it is not likely to produce drug resistance, have the characteristics that rapid-action, curative effect is good.
Description
Technical field
The present invention relates to field of veterinary, in particular to a kind of composition and its prevent infectious laryngotracheitis of chicken
Purposes.
Background technology
Infectious laryngotracheitis of chicken (Infectious laryngotracheitis, ILT) is by chicken infectivity throat tracheae
Chicken is acute, hot, high degree in contact caused by scorching virus (Infectious laryngotracheitis virus, ILTV)
Upper respiratory infectious disease, infected chicken shows as expiratory dyspnea, expectoration band blood mucus, tracheal mucosa oedema and bleeding etc., and causes
It infects chicken death and chicken egg productivity of laying eggs declines, serious economic loss is caused to poultry husbandry.
Currently, in the treatment of the disease, the antiviral drugs such as Ribavirin, amantadine and moroxydine are mainly utilized.
The action target spot of this kind of drug is single, although certain curative effect can be obtained, its many drawback is also increasingly notable, such as is also easy to produce
Drug resistance and make in chicken body that medicament residue is serious, jeopardizes human food's safety, easily decline the speed of growth of chicken group and laying rate,
Cause economic loss etc..Therefore, for infectious laryngotracheitis of chicken, it is badly in need of the medicine of a kind of wide effect of exploitation, safety.
Invention content
The present invention relates to a kind of compositions, can be pharmaceutical composition or functional feedstuff composition.The combination of the present invention
Object can inhibit the propagation of avian infectious laryngotracheitis virus, effectively reduce and suffer from the fowl death rate.
On the one hand, the present invention relates to a kind of compositions, including：(a) lacidipine and (b) his Wei of Dacca.
On the other hand, it is related to the composition of the present invention in preparing the drug for treating or preventing infectious laryngotracheitis of chicken
Purposes.
On the other hand, the composition for being related to the present invention is preparing the animal feed for treating or preventing infectious laryngotracheitis of chicken
In purposes.
Compared with prior art, this composition of the invention passes through both active components of his Wei of lacidipine and Dacca
Between compounding, have potent killing effect to avian infectious laryngotracheitis virus, chicken infectious laryngotracheitis can be inhibited
The propagation of poison effectively reduces and suffers from the fowl death rate, and is not likely to produce drug resistance, has the characteristics that rapid-action, curative effect is good.
Specific implementation mode
Embodiment of the present invention is described in detail below in conjunction with embodiment, but those skilled in the art will
Understand, the following example is merely to illustrate the present invention, and is not construed as limiting the scope of the invention.It is not specified in embodiment specific
Condition person carries out according to conventional conditions or manufacturer's recommended conditions.Reagents or instruments used without specified manufacturer is
The conventional products that can be obtained by commercially available purchase.
It is a discovery of the invention that his two kinds of ingredients of Wei carry out compatibilities by lacidipine and Dacca, can effectively kill avian infectious
Laryngotracheitis virus inhibits the propagation of avian infectious laryngotracheitis virus.Further, due to the chicken infectious laryngotracheitis
Poison propagated strong feature in chicken group, the dosage armed lever that can also change both the above component are aided with general flavone from blackberry lily, green
Ortho acid constituents are taken in the form of drug or feed to chicken group in the season that infectious laryngotracheitis of chicken is easy breaking-out,
The propagation of avian infectious laryngotracheitis virus can be reduced, effectively reduces and suffers from the fowl death rate, to reach prevention chicken infectivity throat gas
The purpose of Guan Yan.
One aspect of the present invention is related to a kind of composition, including：
(a) lacidipine；
(b) his Wei of Dacca；
Optionally (c) general flavone from blackberry lily；
Optionally (d) chlorogenic acid.
One aspect of the present invention is related to first chamber comprising his Wei of lacidipine and Dacca.In some embodiments,
The active component of first chamber is only by his Wei Zucheng of lacidipine and Dacca.
In some embodiments, first chamber can be applied in the diseased chicken with infectious laryngotracheitis of chicken.
Another aspect of the present invention is related to second chamber comprising lacidipine, his Wei, general flavone from blackberry lily and green original of Dacca
Acids.In some embodiments, the active component of second chamber only by lacidipine, his Wei of Dacca, general flavone from blackberry lily and
Chlorogenic acid forms.
In some embodiments, second chamber includes lacidipine, his Wei, irisflorentin and 4- asafoetides of Dacca
Acyl quininic acid.
In some embodiments, second chamber can be used as drug or feed addictive to be applied to infect with chicken
In the diseased chicken of property laryngotracheitis.
In some embodiments, second chamber includes lacidipine, his Wei, general flavone from blackberry lily and chlorogenic acid of Dacca
Class.Wherein, chlorogenic acid is selected from 4-FQA, Isochlorogenic acid B and Isochlorogenic acid C.
In this composition that can be used for preventing infectious laryngotracheitis of chicken：
(a) lacidipine
Lacidipine (Lacidipine), entitled (E) -4- { 2- [3- (carboxylic tertiary butyl) -3- oxo -1- acrylic] of chemistry
Phenyl }-Isosorbide-5-Nitrae-dihydro -2,6- dimethyl -3,5- pyridine-dicarboxylate, structural formula is shown in formula I：
Lacidipine is artificial synthesized micromolecule compound, belongs to special, potent lasting dihydropyridine calcium channel resistance
Stagnant dose, clinically it is mainly used for treating hypertension, main pharmacological includes that the calcium of selective retardance vascular smooth muscle is logical
Peripheral arterial is expanded in road, is reduced peripheral vascular resistance, is reduced blood pressure.
Inventor is the study found that lacidipine can effectively inhibit chicken infectious laryngotracheitis in non-toxic range
Poison invades host cell, so as to be effectively prevented and treated the virus infection caused by avian infectious laryngotracheitis virus；
And lacidipine has clinically had the application of many decades, good security.Therefore, it is to control that can further develop lacidipine
Treat or prevent the drug of avian infectious laryngotracheitis virus infection.
In some embodiments, the amount of lacidipine can be 1~600 parts by weight in composition of the invention, such as
10~550 parts by weight either 50~500 parts by weight either 100~400 parts by weight either 150~350 parts by weight or 200
~300 parts by weight or 230~250 parts by weight.
(b) his Wei of Dacca
His Wei (Daclatasvir) of Dacca is a kind of anti-hepatitis C virus medicine researched and developed by Bristol-Myers Squibb Co., the medicine
Joint Suo Feibuwei (Sofosbuvir) is treated in the 3 type hepatitis patient of gene without hepatic sclerosis, and cure rate is up to 97%.Its structure
As shown in Formula II：
Inventor can significantly increase the anti-chicken of lacidipine the study found that when his Wei of Dacca is used in conjunction with lacidipine
The activity of infectious laryngotracheitis virus.Although its Related Mechanism not yet explore it is clear, it is made sure that both share,
Has the function of synergy.
In some embodiments, the amount of lacidipine can be 1~600 parts by weight in composition of the invention, such as
10~550 parts by weight either 50~500 parts by weight either 100~400 parts by weight either 150~350 parts by weight or 200
~300 parts by weight or 230~250 parts by weight.
(c) general flavone from blackberry lily
General flavone from blackberry lily is the main active in blackberry lily, and Chinese Traditional Medicine is thought, blackberry lily is cold in nature, has heat-clearing solution
The effect of poison, dissolving phlegm, relieving sore-throat, is usually used in heat toxin convulsive seizure due to phlegm-fire Tai knots, abscess of throat, accumulation and obstruction of sputum, cough and asthma.
Inventor is research shows that general flavone from blackberry lily after being used in compounding with lacidipine and his Wei of Dacca, can be passed in anti-chicken
While metachromia laryngotracheitis virus, the propagation of avian infectious laryngotracheitis virus is blocked, this viral infection is effectively inhibited
Propagation of the disease in healthy chicken flock.
Wherein, the content of irisflorentin is 6.72~8.49wt% in general flavone from blackberry lily, in the general flavone from blackberry lily
The content of dichotomitin is 4.05~6.84wt%.
Wherein, inventor is the study found that the suppression of irisflorentin and dichotomitin to avian infectious laryngotracheitis virus
It is more notable to make use, wherein the chemical constitution of irisflorentin is as shown in formula III：
The structure of dichotomitin is as shown in formula IV：
Further, the preparation method of the general flavone from blackberry lily includes：
It uses pH to impregnate blackberry lily medicinal material for 8~9 weak base aqueous solution, is used in combination sonic oscillation to extract, obtains crude extract, then adjust
The pH to 3~5 for saving crude extract, obtains sediment after standing, dry blackberry lily crude extract；
It is again that blackberry lily crude extract is soluble in water, it is extracted, is obtained with petroleum ether, chloroform, ethyl acetate and n-butanol successively
To acetic acid ethyl acetate extract be general flavone from blackberry lily.
Preferably, extraction when, sonic oscillation extraction frequency be 3000-5000HZ, sonic oscillation extraction time be
15-28min。
In some embodiments, the amount of general flavone from blackberry lily can be 1~300 parts by weight, example in composition of the invention
As 2~250 parts by weight either 10~200 parts by weight either 15~150 parts by weight either 20~100 parts by weight or 30~
60 parts by weight or 40~50 parts by weight.
(d) chlorogenic acid
This chlorogenic acid component can be specific chlorogenic acid compound, or comprising chlorogenic acid ingredient
Mixture, such as the extract that is extracted from the posts such as green plum, green coffee, coltsfoot rich in chlorogenic acid ingredient.
Preferably, the chlorogenic acid ingredient mentioned in the present invention refers to：4-FQA, 3,4-, bis- caffeoyl Kuis
Peaceful acid and Isochlorogenic acid C.
In some embodiments, the amount of composition Content of Chlorogenic Acid class of the invention can be 1~300 parts by weight, such as 2
~250 parts by weight either 10~200 parts by weight either 15~150 parts by weight either 20~100 parts by weight or 40~70
Parts by weight or 55~65 parts by weight.
Further, the composition further includes auxiliary material acceptable on the veterinary pharmacy, which includes but not limited to：Adhesive
(such as microcrystalline cellulose, alginates, gelatin and polyvinylpyrrolidone), filler (such as starch, sucrose, glucose and anhydrous lactitol
Acid), disintegrant (such as cross-linked pvp, crosslinked carboxymethyl fecula sodium, croscarmellose sodium and low substituted hydroxy-propyl fiber
Element), lubricant (magnesium stearate, aluminum stearate, talcum, polyethylene glycol, sodium benzoate), wetting agent (such as glycerine), surface-active
Agent (such as hexadecanol) and sorbefacient, corrigent, sweetener, diluent, coating agent.
The feature and performance of the present invention are described in further detail with reference to embodiments：
Embodiment 1
1. experimental animal
The blue grey chicken in healthy commercial generation sea to be selected, is adapted to one week in laboratory before experiment, laboratory temperature is kept for 23~27 DEG C,
Free water is ingested.
2. experiment setting and grouping
Composition is set as two factors, each factor is one group, to each factor according to different proportioning modes into
Row comparative test.Wherein, first group is his Wei of lacidipine and Dacca；Second group be lacidipine, his Wei of Dacca, blackberry lily it is always yellow
Ketone and chlorogenic acid.
● first group：The composition of his Wei of lacidipine and Dacca is tested：
(1) experimental method
Dai Hailan ash chickens are randomly divided into 10 groups, every group 10, wherein the 1st group be blank control group (healthy group), the 2nd
Group is the model group of infection infectious laryngotracheitis of chicken, and the 3rd group is positive controls (positive drug is amantadine), the 4th group
It is respectively 2 groups of 1 group of comparative example and comparative example with the 5th group, the 5th~10 group is respectively Examples 1 to 5 group.
Each group chicken locellus isolated rearing, in addition to the 1st group, the strong venom of Dai Hailan ash chicken inoculation ILTV in other groups for 24 hours after,
In addition to blank control group, model group and positive controls, other several groups ingredient equivalents according to table 1 are configured to distillation aqueous suspension
Gastric infusion, blank control group, model group give the water of same volume, and the amantadine that positive drug group gives same volume is molten
Liquid (is administered) by 5mg/kg.Successive administration one week, stops observation post administration 10d, records the death rate, effective percentage and the cure rate of each group,
It is shown in Table 2.
The embodiment and comparative example of 1. first chamber of table
(2) experimental result
2. each group experimental result of table
Find that embodiment 1 is compared with comparative example 1 and comparative example 2, component proportion 1 through experiment：1 embodiment 1 is right
The curative effect (cure rate) for infecting the diseased chicken of avian infectious laryngotracheitis virus is not only independent better than any of which component
The comparative example 1 and 2 of embodiment, and more than the cure rate summation of both.Examples 1 to 5 group can be shown compared with model group
Show the curative effect to diseased chicken with writing, and its therapeutic effect is equivalent to or is better than positive controls.It is indicated above that first
Composition (including his Wei of lacidipine and Dacca is according to 1：1、1：4 or 1：10 combinations) play good synergistic synergy
Effect, anti-avian infectious laryngotracheitis virus significant effect.
● second group：The composition experiment of lacidipine, Dacca his Wei, general flavone from blackberry lily and chlorogenic acid：
(1) experimental method
Dai Hailan ash chickens are randomly divided into 6 groups, every group 10, wherein the 1st group be blank control group (healthy group), the 2nd group
To infect the model group of infectious laryngotracheitis of chicken, the 3rd group is positive controls (positive drug is amantadine), the 4th~6 group
Respectively embodiment 6 ,~8 groups.
Each group chicken locellus isolated rearing, in addition to the 1st group, the strong venom of Dai Hailan ash chicken inoculation ILTV in other groups for 24 hours after,
In addition to blank control group, model group and positive controls, other several groups ingredient equivalents according to table 3 are configured to distillation aqueous suspension
Gastric infusion, blank control group, model group give the water of same volume, and the amantadine that positive drug group gives same volume is molten
Liquid (is administered) by 5mg/kg.Successive administration one week, stops observation post administration 10d, records the death rate, effective percentage and the cure rate of each group,
It is shown in Table 4.
The embodiment and comparative example of 3. second chamber of table
Note：1 Content of Chlorogenic Acid class of table is 4-FQA.
(2) experimental result
4. each group experimental result of table
By table 4 as it can be seen that the curative effect of the diseased chicken of 6~8 pairs of infection avian infectious laryngotracheitis virus of embodiment (is cured
Rate) it is better than Examples 1 to 5, and it is superior to positive controls.It is indicated above that general flavone from blackberry lily and chlorogenic acid can enhance drawing
The anti-avian infectious laryngotracheitis virus effect of his Wei of western Horizon Yu Dacca.
Although illustrate and describing the present invention with specific embodiment, it will be appreciated that without departing substantially from the present invention's
Many other change and modification can be made in the case of spirit and scope.It is, therefore, intended that in the following claims
Including belonging to all such changes and modifications in the scope of the invention.
Claims (10)
1. a kind of composition, which is characterized in that it includes：(a) lacidipine and (b) his Wei of Dacca.
2. composition according to claim 1, which is characterized in that the composition includes：
(a) 1~600 parts by weight of lacidipine；
(b) his 1~600 parts by weight of Wei of Dacca.
3. composition according to claim 1, which is characterized in that the composition further comprises：(c) general flavone from blackberry lily
And (d) chlorogenic acid.
4. composition according to claim 3, which is characterized in that it includes：
(c) general flavone from blackberry lily 1~300；
(d) 1~300 parts by weight of chlorogenic acid.
5. composition according to claim 3, which is characterized in that the content of irisflorentin in the general flavone from blackberry lily
For 6.72~8.49wt%, the content of dichotomitin is 4.05~6.84wt% in the general flavone from blackberry lily.
6. composition according to claim 4, which is characterized in that the preparation method of the general flavone from blackberry lily includes：
It uses pH to impregnate blackberry lily medicinal material for 8~9 weak base aqueous solution, is used in combination sonic oscillation to extract, obtains crude extract, then adjust institute
The pH to 3~5 of crude extract is stated, obtains sediment after standing, dry blackberry lily crude extract；
It is again that the blackberry lily crude extract is soluble in water, it is extracted, is obtained with petroleum ether, chloroform, ethyl acetate and n-butanol successively
To acetic acid ethyl acetate extract be the general flavone from blackberry lily.
7. composition according to claim 6, which is characterized in that the frequency of the sonic oscillation extraction is 3000-
The time of 5000HZ, the sonic oscillation extraction are 15-28min.
8. composition according to claim 3, which is characterized in that the chlorogenic acid is selected from 4-FQA, 3,
4- dicaffeoylquinic acids and Isochlorogenic acid C.
9. a kind of preparing treatment or prevention infectious laryngotracheitis of chicken according to claim 1~8 any one of them composition
Drug in purposes.
10. a kind of preparing treatment or prevention infectious laryngotracheitis of chicken according to claim 1~8 any one of them composition
Animal feed in purposes.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810720166.9A CN108619143A (en) | 2018-07-03 | 2018-07-03 | A kind of composition and its purposes for preventing infectious laryngotracheitis of chicken |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810720166.9A CN108619143A (en) | 2018-07-03 | 2018-07-03 | A kind of composition and its purposes for preventing infectious laryngotracheitis of chicken |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108619143A true CN108619143A (en) | 2018-10-09 |
Family
ID=63689478
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810720166.9A Pending CN108619143A (en) | 2018-07-03 | 2018-07-03 | A kind of composition and its purposes for preventing infectious laryngotracheitis of chicken |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108619143A (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106511343A (en) * | 2016-12-28 | 2017-03-22 | 中国科学院武汉病毒研究所 | Application of lacidipine to preparing medicines for treating arenavirus infection |
-
2018
- 2018-07-03 CN CN201810720166.9A patent/CN108619143A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106511343A (en) * | 2016-12-28 | 2017-03-22 | 中国科学院武汉病毒研究所 | Application of lacidipine to preparing medicines for treating arenavirus infection |
Non-Patent Citations (5)
| Title |
|---|
| 周志娥等: "绿原酸、异绿原酸A对大肠杆菌的抑菌机制", 《食品科技》 * |
| 张杰等: "射干化学成分研究", 《安徽农业科学》 * |
| 李英娜等: "射干总黄酮的提取工艺研究", 《中南药学》 * |
| 茹仁萍等: "《抗感染药物临床合理应用手册》", 30 November 2016, 中国医药科技出版社 * |
| 郝树松: "鸡传染性喉气管炎诊断与治疗", 《中国畜牧兽医文摘》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102151256A (en) | Application of protocatechuic acid in preparation of drugs for preventing and controlling livestock and poultry virus infectious diseases | |
| CN103687599A (en) | The use of chloroquine, chlorpromazine, derivatives thereof, or mixtures thereof in preparing medications for treating and/or preventing pulmonary infection and injury | |
| CN104304679B (en) | A kind of B B-complex C, E immune polysaccharide microemulsion preparation and its preparation method and application | |
| CN113633649A (en) | Application of combined preparation of Reidesciclovir and nucleoside thereof in resisting porcine epidemic diarrhea virus | |
| CN109568301A (en) | A kind of gallic acid, Rhein compound prescription preparation method and applications | |
| CN107158087A (en) | It is a kind of to prevent Chinese medicine composition of hog cholera and preparation method thereof | |
| RU2678105C2 (en) | Application of taurine for prevention and / or treatment of diseases caused by coronaviruses viruses and / or rotaviruses | |
| JP2022019937A (en) | Composition for preventing or treating chronic or acute virus infection and/or sepsis in humans or animals | |
| KR20220012317A (en) | Use of a complex of an angiotensin II receptor antagonist metabolite and a NEP inhibitor in the treatment of heart failure | |
| CN108619143A (en) | A kind of composition and its purposes for preventing infectious laryngotracheitis of chicken | |
| CN112336728A (en) | Application of HHT in preparing human beta-coronavirus replication inhibitor | |
| CN107661416A (en) | A kind of traditional Chinese medicine extraction compound pharmaceutical for preventing and treating livestock and birds respiratory disease | |
| CN113786404B (en) | Use of bromophenol-pyrazoline compounds in treatment of avian coronavirus diseases | |
| CN109012185A (en) | Membrane separation technique takes orally the application in liquid preparing process in cordate houttuynia a kind of reed mentioned in ancient books indigo plant | |
| CN102379920B (en) | Veterinary antiviral and antifebrile drug composition | |
| CN109718252A (en) | American-cockroach-extract treats and prevents the application in chemotherapy cause intestinal mucosa inflammation drug in preparation | |
| CN103316103B (en) | Coccidian-expelling and dysentery-stopping mixture for livestock and preparation method thereof | |
| CN114917285B (en) | Application of polysaccharide compound in medicine for preventing and treating respiratory tract virus infection | |
| CN112741826A (en) | New application of niclosamide | |
| CN114146078A (en) | Application of ethyl p-hydroxybenzoate in resisting coronavirus infection | |
| CN101711795B (en) | Veterinary antipyretic and antiviral medicine composite | |
| CN106822152B (en) | Pharmaceutical composition and application thereof | |
| CN110721312B (en) | Pharmaceutical composition for treating infantile respiratory tract infection and related preparation thereof | |
| CN102614224B (en) | Novel medical application of propolis total flavonoid | |
| CN113633652B (en) | Application of liquiritin in preparing medicament for treating or preventing enterovirus71 type infection |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20181009 |
|
| RJ01 | Rejection of invention patent application after publication |